ASCO 2016 Poster Presented

IITRI co-authored a poster presented at the recent American Society of Clinical Oncology (ASCO) meeting in Chicago, IL.

The poster, A novel single domain antibody (sdAb) SBT-100 to target intracellular STAT3 to affect growth and regression of human triple negative breast cancer (TNBC) cells was the result of an ongoing collaboration between IITRI and Sunanda Singh, Singh Biotechnology, LLC.

TNBC, a treatment-resistant form of breast cancer, has limited chemotherapeutic options and poor prognosis associated with the diagnosis. Dr. Singh has been partnering with IITRI for mouse xenograph studies evaluating the efficacy of his single-domain antibody (sdAb) targeting intracellular STAT3. STAT3 has been shown to play an important role in the pathogenesis of TNBC.

The study showed inhibition of TNBC-derived tumor growth by SBT-100 in the mouse xenograph model, an encouraging indicator that the sdAb may also be effective in humans.

The poster abstract is published in J Clin Oncol 34, 2016 (suppl; abstr 1083).